Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 18Myeloid 8Gastrointestinal 5Tumor-Agnostic 1Sarcoma 1Lymphoid 1Classical hematology 1CNS 1

Conditions

Lymphoma, Follicular 1Chondrosarcoma 1

Interventions

Radiotherapy 137Cyclophosphamide 132Temozolomide 116Doxorubicin 99Filgrastim 68Ifosfamide 64Gemcitabine 58Etoposide 55Bevacizumab 51Imatinib Mesylate 50fludarabine phosphate 49Irinotecan 46pembrolizumab 45Peripheral Blood Stem Cell Transplantation 45pazopanib 43Magnetic Resonance Spectroscopy 42Methotrexate 40Carboplatin 40Busulfan 40Vincristine 38Surgical Procedures, Operative 37Nivolumab 37Melphalan 37Cisplatin 36Radiation 34Blood Specimen Collection 33Mycophenolic Acid 31Cyclosporine 31Docetaxel 29Trabectedin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × ivosidenib × Sarcoma × Clear all
NCT04278781 2026-04-23

AG-120 in People With IDH1 Mutant Chondrosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
6 enrolled
LymphoidSarcoma

Chondrosarcoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡